TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05759442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride (HCL)
Description: Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple cider vinegar
Description: Apple cider vinegar aimed at improving glycemic indices in Prediabetics
Study: NCT05371574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine group
Description: Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine group
Description: Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
Study: NCT04711473

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy Only
Description: Mailed letter asking participants to complete CRC screening by colonoscopy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: Mailed letter and FIT test asking participants to complete CRC screening by their choice of either colonoscopy or mailed FIT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT Only
Description: Mailed letter and FIT test asking participants to complete CRC screening by mailed FIT
Study: NCT05790603

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group with TR-Band
Description: TR-Band will be inflated with 15 mL of air The band will be deflated with 1 mL of air hourly for the following 2 hours after the procedure. After 3 hours, the band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated with appropriate volume of air until bleeding stops .
Study: NCT04939220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEE with SGA
Description: SGA Placement and maintenance with inhalational anesthetic or propofol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEE with Deep Sedation
Description: Deep sedation with propofol and natural airway
Study: NCT04033029

Intervention type: DEVICE
Intervention: Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)
Description: CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
Study: NCT04825067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Sensor measurements
Description: The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
Study: NCT05733273

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic hamstring exercise program
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single leg bridge exercise program
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring razor curl
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
Study: NCT05732883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT06438796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation
Study: NCT04033029

Intervention type: DRUG
Intervention: Antibiotics
Description: Antibiotic concentration-time data will be collected and analyzed.
Study: NCT06268366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Three exercises consisting of stretching and strengthening specific to the movement pattern dysfunction scored by Symmio will be prescribed to the participants. The exercises are standardized and assigned within the Symmio application with video instruction and guidance.
Study: NCT06319066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthotic wedge
Description: The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthotic wedge
Description: The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CFO
Description: The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CFO
Description: The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CFO
Description: The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
Study: NCT06496698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple Interrupted Suture
Description: In the control group, simple interrupted sutures will be used for wound closure after surgical repair of ankle fractures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcuticular Suture
Description: In the experimental group, subcuticular sutures will be used for wound closure after surgical repair of ankle fractures.
Study: NCT05103540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive SEM-Based Program
Description: The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
Study: NCT04765449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotoxic T Lymphocytes
Description: Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
Study: NCT05853289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody
Description: MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
Study: NCT05932160

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% glucose
Description: Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lactated ringers
Description: Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.
Study: NCT04846634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
Description: A cycle of treatment is defined as 21 days of once daily treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
Description: A cycle of treatment is defined as 21 days of once daily treatment.
Study: NCT06529848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The training sessions are consist of cycling and as follows: a 10 min warm-up at a light intensity, 20-35 min of cycling exercise in intervals at varying intensities from light (\~60% of max heart rate) to more intensive (80-90% of max heart rate) and ending with 5 min of warm-down at a light intensity. The training intensity will be progressive during the course of the intervention period. The cycling training sessions are supervised .~Home training is allowed up to once a week if participants are able to adhere to the prescribed intensity levels.~Training sessions are closely monitored to ensure effectiveness and safety. This includes heart rate monitoring, perceived exertion assessment.
Study: NCT05547165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Patent Ductus Arteriosus Closure (PPC)
Description: Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Patent Ductus Arteriosus Closure (PPC)
Description: Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Responsive Management Intervention
Description: Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram, cardiac
Description: An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiogram, cardiac
Description: An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions.
Study: NCT05614284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtuos
Description: Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtuos
Description: Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.
Study: NCT05953012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMC-403
Description: PMC-403 will be administered Intravitreal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMC-403
Description: PMC-403 will be administered Intravitreal.
Study: NCT05071430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB-01
Description: HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HB-1 matched placebo
Study: NCT04846634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab+Anlotinib
Description: A cycle of treatment is defined as 21 days of once daily treatment.
Study: NCT04974931

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PREVENA Incision Management System
Description: Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
Study: NCT05318820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
Study: NCT06382935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probin Pocket Depth reduction
Description: Probin Pocket Depth reduction in millimetres before and after treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probin Pocket Depth reduction
Description: Probin Pocket Depth reduction in millimetres before and after treatment
Study: NCT04871594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: On day 1, 22, and 43 240mg
Study: NCT06186531

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoSERM
Description: PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
Study: NCT06161220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa capsule
Description: Dose: 4x 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa capsule
Description: Dose: 4x 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbidopa capsule
Description: Dose: 4x 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Tablets, USP
Description: Dose: 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Tablets, USP
Description: Dose: 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Tablets, USP
Description: Dose: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules matching the carbidopa capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching the carbidopa capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching the carbidopa capsules
Study: NCT04538144

Intervention type: OTHER
Intervention: Simulated heat wave
Description: Individuals will be exposed to thermoneutral climate conditions and two simulated heat wave conditions.

Intervention type: OTHER
Intervention: Simulated heat wave
Description: Individuals will be exposed to thermoneutral climate conditions and two simulated heat wave conditions.
Study: NCT06143670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: 0.454% w/w SnF2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride toothpaste
Description: 0.243% w/w Sodium fluoride
Study: NCT04748315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEMT(1:1)
Description: Soccer trainning protocolo will be performed on an work to rest ratio 1:1 and the trainning volume will consist of 1 set and 6 repetitions per set

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEMT (1:3)
Description: Soccer trainning protocolo will be performed on an work to rest ratio 1:3 and the trainning volume will consist of 1 set and 6 repetitions per set
Study: NCT05807984

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion radiation therapy DT: 74Gy/20 fractions
Description: patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
Study: NCT05597072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Less people within the OR but longer waiting time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: More people in the OR but shorter waiting time
Study: NCT05170789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab, Selinexor, and Dexamethasone (ESd)
Description: This is a single-arm, interventional, phase II clinical trial, in which the anticipated 18 enrolled patients will receive the trial drug, a combination of Elotuzumab, Selinexor, and Dexamethasone in monthly cycles. The study tests the theory of synergy between these drugs, as detailed in the study description above.